UNLABELLED: High titer antibodies to type 1 interferons have been recently reported as being highly specific for patients with autoimmune polyglandular syndrome type 1 (APS1) in Finnish and Norwegian patients with mutations in the AIRE gene. Those studies employed a complex neutralization assay to define the type 1 interferon autoantibodies. Here we have established a competitive europium time resolved fluorescence assay for IFN-alpha autoantibodies and measured sera from subjects with APS1, first degree relatives of APS1 patients, patients with Addison's disease or Type 1 diabetes. The europium-based immunoassay utilizes plate bound human IFN-alpha incubated with sera with or without competition with fluid phase IFN-alpha, followed by anti-IgG biotinylated antibody and detection with streptavidin-europium. The index of IFN-alpha Ab was calculated as (CPS (Counts per second) without competition-CPS with competition)/(CPS positive standard sera without competition-CPS positive standard sera with competition). RESULTS are reported for raw CPS and indices and are compared across the different subjects. RESULTS: For normal controls (n=100) CPS without competition were 31,237+/-17,328 CPS while after subtracting the competition value, the results were -6563+/-10,303 CPS. The initial APS1 patient (used to create the index as 1.0) gave 394,063 CPS without competition and a delta of 363,662+/-31,587 CPS with competition. Scatchard plot analysis of this patient sample revealed a high avidity for IFN-alpha (K(d) of 0.5 nM). The CPS, delta, and index for 6/7 APS1 patients were strongly positive and 3 standard deviations or more above that of the normal controls. Using a cut-off of 2 standard deviations above normal controls, relatives of APS1 patients were negative for type I interferon autoantibodies as were 71 patients with Addison's disease (non-APS1) and 141 Type 1 diabetes patients. This simple high throughput competitive europium time resolved fluorescence assay had a sensitivity of > or =86% or greater and a specificity of >99.5%.
UNLABELLED: High titer antibodies to type 1 interferons have been recently reported as being highly specific for patients with autoimmune polyglandular syndrome type 1 (APS1) in Finnish and Norwegian patients with mutations in the AIRE gene. Those studies employed a complex neutralization assay to define the type 1 interferon autoantibodies. Here we have established a competitive europium time resolved fluorescence assay for IFN-alpha autoantibodies and measured sera from subjects with APS1, first degree relatives of APS1patients, patients with Addison's disease or Type 1 diabetes. The europium-based immunoassay utilizes plate bound humanIFN-alpha incubated with sera with or without competition with fluid phase IFN-alpha, followed by anti-IgG biotinylated antibody and detection with streptavidin-europium. The index of IFN-alpha Ab was calculated as (CPS (Counts per second) without competition-CPS with competition)/(CPS positive standard sera without competition-CPS positive standard sera with competition). RESULTS are reported for raw CPS and indices and are compared across the different subjects. RESULTS: For normal controls (n=100) CPS without competition were 31,237+/-17,328 CPS while after subtracting the competition value, the results were -6563+/-10,303 CPS. The initial APS1patient (used to create the index as 1.0) gave 394,063 CPS without competition and a delta of 363,662+/-31,587 CPS with competition. Scatchard plot analysis of this patient sample revealed a high avidity for IFN-alpha (K(d) of 0.5 nM). The CPS, delta, and index for 6/7 APS1patients were strongly positive and 3 standard deviations or more above that of the normal controls. Using a cut-off of 2 standard deviations above normal controls, relatives of APS1patients were negative for type I interferon autoantibodies as were 71 patients with Addison's disease (non-APS1) and 141 Type 1 diabetespatients. This simple high throughput competitive europium time resolved fluorescence assay had a sensitivity of > or =86% or greater and a specificity of >99.5%.
Authors: K Nagamine; P Peterson; H S Scott; J Kudoh; S Minoshima; M Heino; K J Krohn; M D Lalioti; P E Mullis; S E Antonarakis; K Kawasaki; S Asakawa; F Ito; N Shimizu Journal: Nat Genet Date: 1997-12 Impact factor: 38.330
Authors: H S Scott; M Heino; P Peterson; L Mittaz; M D Lalioti; C Betterle; A Cohen; M Seri; M Lerone; G Romeo; P Collin; M Salo; R Metcalfe; A Weetman; M P Papasavvas; C Rossier; K Nagamine; J Kudoh; N Shimizu; K J Krohn; S E Antonarakis Journal: Mol Endocrinol Date: 1998-08
Authors: Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: Jason DeVoss; Yafei Hou; Kellsey Johannes; Wen Lu; Gregory I Liou; John Rinn; Howard Chang; Rachel R Caspi; Rachel Caspi; Lawrence Fong; Mark S Anderson Journal: J Exp Med Date: 2006-11-20 Impact factor: 14.307
Authors: Jeffrey A Bluestone; Hugh Auchincloss; Gerald T Nepom; Daniel Rotrosen; E William St Clair; Laurence A Turka Journal: Nat Rev Immunol Date: 2010-11 Impact factor: 53.106
Authors: Li Zhang; Pilar Londono; Liping Yu; Stephen Grimes; Peter Blackburn; Peter Gottlieb; George S Eisenbarth Journal: Autoimmunity Date: 2014-05-01 Impact factor: 2.815
Authors: Taylor M Triolo; Erin E Baschal; Taylor K Armstrong; Carrie S Toews; Pamela R Fain; Marian J Rewers; Liping Yu; Dongmei Miao; George S Eisenbarth; Peter A Gottlieb; Jennifer M Barker Journal: J Clin Endocrinol Metab Date: 2009-10-09 Impact factor: 5.958
Authors: Anthony K Shum; Mohammad Alimohammadi; Catherine L Tan; Mickie H Cheng; Todd C Metzger; Christopher S Law; Wint Lwin; Jaakko Perheentupa; Helene Bour-Jordan; Jean Claude Carel; Eystein S Husebye; Filippo De Luca; Christer Janson; Ravishankar Sargur; Noémie Dubois; Merja Kajosaari; Paul J Wolters; Harold A Chapman; Olle Kämpe; Mark S Anderson Journal: Sci Transl Med Date: 2013-10-09 Impact factor: 17.956